SLC5A2 and heart failure: Specifically, in HFpEF and CAD, studies like DELIVER and EMPEROR-Preserved have shown that SGLT2 inhibitors reduced mortality and heart failure hospitalizations and improved symptoms, leading to their strong recommendation for HFpEF in 2023 ESC guidelines.